NFKB1 and myeloproliferative disorder: Kleppe et al. have shown that BET Inhibition with (JQ1) attenuates NF-κB transactivation in vivo and that combined ruxolitinib/JQ1 delays JAK inhibitor persistence and shows efficacy against MPN cells [8].